ArticleEuropean journal of pediatrics2026
Emicizumab prophylaxis beyond clinical trials: a multicenter, prospective real-world study of pediatric hemophilia patients with and without inhibitors.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emicizumab has improved prophylactic management of hemophilia A (HA), offering effective bleed prevention independent of factor VIII (FVIII) inhibitor status. However, prospective real-world pediatric data from low- and middle-income settings remain limited. We conducted a prospective cohort study of 72 children (< 18 years) with HA receiving subcutaneous emicizumab prophylaxis for 12 months. The cohort comprised 70 patients with severe HA and 2 with moderate HA with severe bleeding phenotype. Patients included both inhibitor-positive and inhibitor-negative children. Outcomes included annualized bleeding rate (ABR), joint health assessed by Hemophilia Joint Health Score version 2.1 (HJHS 2.1), and functional capacity measured by the Functional Independence Score in Hemophilia (FISH). The. median ABR decreased from 40 (IQR 36-48) at baseline to 0 (IQR 0-0) after 12 months (P < 0.001), with 79.16% of children experiencing zero treated bleeds. AJBR was 0 in 86.1% of patients, and all target joints resolved by 12 months. The median HJHS improved from 15 (IQR 7-22) to 9 (IQR 3-14) (P < 0.001), and mean FISH score increased from 20.65 ± 4.25 to 26.02 ± 3.57 (P < 0.001), with greatest improvements in squatting, running, and stair climbing. Reductions in ABR, HJHS, and FISH were comparable between inhibitor-positive and inhibitor-negative patients.
conclusionEmicizumab prophylaxis provides profound bleed control and meaningful improvements in joint and functional outcomes in children with HA, regardless of inhibitor status, supporting its use as standard pediatric prophylaxis in routine clinical practice. WHAT IS KNOWN: • Emicizumab effectively reduces bleeding in children with hemophilia A. • Prospective real-world pediatric data in low- and middle-income settings remain limited. WHAT IS NEW: • This study showed near-complete bleed control, full target joint resolution. • Comparable benefits were observed in children with and without inhibitors in a prospective real-world setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.